An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: A 7-Year institutional experience of hepatitis screening

Oncologist

Volumn 16, Issue 5, 2011, Pages 579-584

  Leung, Christopher ^a   Tsoi, Edward ^a   Burns, Gareth ^a   Sieverta, William ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Hepatitis B reactivation; Hepatitis B screening; Lymphoma; R CHOP chemotherapy; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; CHILD; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SCREENING TEST; SIDE EFFECT; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; VIRUS ACTIVATION;

EID: 79956284897     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0182     Document Type: Review

References (28)

1. World Health Organization. Hepatitis B. Fact Sheet No 204. Revised August 2008. Available at http://www.who.int/mediacentre/factsheets/fs204, accessed March 19, 2011.
2. van der Sande MA, Waight P, Mendy M et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006;193: 1528-1535.
3. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990;(8 suppl):S18-S20; discussion S21-S23.
4. Zell JA, Yoon EJ, Ignatius Ou SH et al. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005;16: 83-85.
5. Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27: 4578-4584.
6. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-662.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-242.
8. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
9. Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008;47:844-853.
10. National Comprehensive Cancer Network. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas. Available at http://www.nccn.org, accessed February 24, 2010.
11. Zelenetz AD, Abramson JS, Advani RH et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288-334.
12. Tawk HM, Vickery K, Bisset L et al. The current pattern of hepatitis B virus infection in Australia. J Viral Hepat 2006;13:206-215.
13. Sydney South West Pathology Service (SSWPS). Results. Available at http://www.sswahs.nsw.gov.au/sswps/default_hb.htm, accessed March 18, 2011.
14. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
15. Koo YX, Tan DS, Tan BH et al. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol 2009;27:2570-2571; author reply 2571-2572.
16. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
17. Koo YX, Tan DS, Tan IB et al. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009;150:655-656.
18. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HB sAg and positive for HB sAb and HB cAb. J Infect Chemother 2005;11:189-191.
19. Niitsu N, Hagiwara Y, Tanae K et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-5100.
20. Loomba R, Rowley A, Wesley R et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
21. Katz LH, Fraser A, Gafter-Gvili A et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat 2008;15:89-102.
22. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: A meta-analysis. Liver Int 2008;28:28-38.
23. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
24. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D et al. Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment? Am J Hematol 2008;83:673-675.
25. Li HR, Huang JJ, Guo HQ et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2010 Nov 5. doi: 10.1111/j.1365-2893.2010.01386.x. [Epub ahead of print].
26. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996;87:1202.
27. Kanda T, Yokosuka O, Imazeki F et al. Corticosteroids and lamivudine combined to treat acute severe flare-up in a chronic hepatitis B and C patient. J Gastroenterol Hepatol 2004;19:238-239.
28. Khaled Y, Hanbali A. Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. Am J Hematol 2007;82:688.